Development of a preliminary composite disease activity index in psoriatic arthritis.

Hdl Handle:
http://hdl.handle.net/10147/207610
Title:
Development of a preliminary composite disease activity index in psoriatic arthritis.
Authors:
Mumtaz, Aizad; Gallagher, Phil; Kirby, Brian; Waxman, Robin; Coates, Laura C; Veale J, Douglas; Helliwell, Philip; FitzGerald, Oliver
Affiliation:
Department of Rheumatology, St Vincent's University Hospital, University College , Dublin, Dublin, Ireland.
Citation:
Ann Rheum Dis. 2011 Feb;70(2):272-7. Epub 2010 Nov 29.
Journal:
Annals of the rheumatic diseases
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207610
DOI:
10.1136/ard.2010.129379
PubMed ID:
21115550
Abstract:
OBJECTIVES: To develop a preliminary composite psoriatic disease activity index (CPDAI) for psoriasis and psoriatic arthritis. METHODS: Five domains were assessed and specific instruments were employed for each domain to determine the extent of domain involvement and the effect of that involvement on quality of life/function. Disease activity for each domain was then graded from 0 to 3 giving a CPDAI range of 0-15. Patient and physician global disease activity measures were also recorded and an independent physician was asked to indicate if treatment change was required. Bivariate correlation analysis was performed. Factor, tree analysis and standardised response means were also calculated. RESULTS: Significant correlation was seen between CPDAI and both patient (r = 0.834) and physician (r = 0.825) global disease activity assessments (p = 0.01). Tree analysis revealed that 96.3% of patients had their treatment changed when CPDAI values were greater than 6; no patient had their treatment changed when CPDAI values were less than 5. CONCLUSION: CPDAI correlates well with patient and physician global disease activity assessments and is an effective tool that clearly distinguishes those who require a treatment change from those who do not.
Language:
eng
MeSH:
Adult; Aged; Antirheumatic Agents/therapeutic use; Arthritis, Psoriatic/*diagnosis/drug therapy; Drug Monitoring/methods; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Psoriasis/diagnosis/drug therapy; Quality of Life; *Severity of Illness Index; Treatment Outcome
ISSN:
1468-2060 (Electronic); 0003-4967 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorMumtaz, Aizaden_GB
dc.contributor.authorGallagher, Philen_GB
dc.contributor.authorKirby, Brianen_GB
dc.contributor.authorWaxman, Robinen_GB
dc.contributor.authorCoates, Laura Cen_GB
dc.contributor.authorVeale J, Douglasen_GB
dc.contributor.authorHelliwell, Philipen_GB
dc.contributor.authorFitzGerald, Oliveren_GB
dc.date.accessioned2012-02-01T10:32:48Z-
dc.date.available2012-02-01T10:32:48Z-
dc.date.issued2012-02-01T10:32:48Z-
dc.identifier.citationAnn Rheum Dis. 2011 Feb;70(2):272-7. Epub 2010 Nov 29.en_GB
dc.identifier.issn1468-2060 (Electronic)en_GB
dc.identifier.issn0003-4967 (Linking)en_GB
dc.identifier.pmid21115550en_GB
dc.identifier.doi10.1136/ard.2010.129379en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207610-
dc.description.abstractOBJECTIVES: To develop a preliminary composite psoriatic disease activity index (CPDAI) for psoriasis and psoriatic arthritis. METHODS: Five domains were assessed and specific instruments were employed for each domain to determine the extent of domain involvement and the effect of that involvement on quality of life/function. Disease activity for each domain was then graded from 0 to 3 giving a CPDAI range of 0-15. Patient and physician global disease activity measures were also recorded and an independent physician was asked to indicate if treatment change was required. Bivariate correlation analysis was performed. Factor, tree analysis and standardised response means were also calculated. RESULTS: Significant correlation was seen between CPDAI and both patient (r = 0.834) and physician (r = 0.825) global disease activity assessments (p = 0.01). Tree analysis revealed that 96.3% of patients had their treatment changed when CPDAI values were greater than 6; no patient had their treatment changed when CPDAI values were less than 5. CONCLUSION: CPDAI correlates well with patient and physician global disease activity assessments and is an effective tool that clearly distinguishes those who require a treatment change from those who do not.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshAgeden_GB
dc.subject.meshAntirheumatic Agents/therapeutic useen_GB
dc.subject.meshArthritis, Psoriatic/*diagnosis/drug therapyen_GB
dc.subject.meshDrug Monitoring/methodsen_GB
dc.subject.meshEpidemiologic Methodsen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshPsoriasis/diagnosis/drug therapyen_GB
dc.subject.meshQuality of Lifeen_GB
dc.subject.mesh*Severity of Illness Indexen_GB
dc.subject.meshTreatment Outcomeen_GB
dc.titleDevelopment of a preliminary composite disease activity index in psoriatic arthritis.en_GB
dc.contributor.departmentDepartment of Rheumatology, St Vincent's University Hospital, University College , Dublin, Dublin, Ireland.en_GB
dc.identifier.journalAnnals of the rheumatic diseasesen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.